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Abstract Regulation of the sarco(endo)plasmic reticulum Ca2+-
ATPase (SERCA 2a) depends on the phosphorylation state of
phospholamban (PLB). When PLB is phosphorylated, its
inhibitory effect towards SERCA 2a is relieved, leading to an
enhanced myocardial performance. This process is reversed by a
sarcoplasmic reticulum (SR)-associated type 1 protein phospha-
tase (PP1) composed of a catalytic subunit PP1C and a
regulatory subunit GM. Human GM and PLB have been
produced in an in vitro transcription/translation system and used
for co-immunoprecipitation and biosensor experiments. The
detected interaction between the two partners suggests that
cardiac PP1 is targeted to PLB via GM and we believe that this
process occurs with the identified transmembrane domains of the
two proteins. Thus, the interaction between PLB and GM may
represent a specific way to modulate the SR function in human
cardiac muscle.
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1. Introduction
Phospholamban (PLB) is a 52-amino acid protein that reg-
ulates the activity of the cardiac sarco(endo)plasmic reticulum
calcium ATPase (SERCA 2a). The physiological role of PLB
on the activity of the calcium ATPase has been demonstrated
using transgenic models in which the intracellular calcium
transient and the myocardial relaxation are directly related
to the level of expressed PLB [1]. Similarly, agents that inhibit
the interaction between PLB and SERCA 2a, such as ellagic
acid, can increase the activity of the calcium pump [2]. In a
dephosphorylated form, PLB decreases the a⁄nity of SERCA
2a for calcium and phosphorylation of PLB removes its in-
hibitory e¡ect towards SERCA 2a [3] which is able to pump
more rapidly the Ca2 from the cytosol into the SR [4]; this
latter e¡ect is correlated with an enhanced relaxation of the
heart [5]. Phosphorylation of PLB at distinct sites by cAMP-
dependent (at serine 16) and calmodulin-dependent (at threo-
nine 17) protein kinases is reversed by a sarcoplasmic reticu-
lum (SR)-associated protein phosphatase. MacDougall et al.
[6] have shown that the major protein phosphatase associated
with the cardiac SR is a type 1 protein phosphatase, one of
the most important serine/threonine protein phosphatases in
eukaryotic cells. Inhibitors of such phosphatases, like calycu-
lin A, okadaic acid or tautomycin, have been shown to im-
prove cardiac relaxation and calcium uptake by the SR [7,8].
Furthermore, we have recently reported that this e¡ect is di-
rectly associated with an increased amount of phosphorylated
PLB [9].
Although type 1 protein phosphatases are ubiquitously dis-
tributed, several lines of evidence suggest that like other en-
zymes they do not reach their physiological substrates by
simple di¡usion within cells. In contrast, it appears that phos-
phatases are frequently directed to particular loci in the vicin-
ity of their substrates by interaction with targeting subunits
[10]. Type 1 protein phosphatases are typical examples of
heterodimer enzymes involved in controlling diverse cellular
functions including glycogen metabolism, exit from mitosis,
splicing of RNA and muscle contraction [11] where the
same catalytic subunit (PP1C) is complexed to di¡erent tar-
geting or regulatory subunits conferring substrate speci¢city.
In the heart, this heterodimer called PP1 (also known as
PP1G) is composed of a 37-kDa catalytic subunit PP1C com-
plexed to a larger subunit called GM (also known as G, RG1,
PPP1R3) which is responsible for the association of PP1 with
SR membranes [6]. In human, GM is one of the several reg-
ulatory subunits which have been isolated and characterised.
Although GM, a 1122-residue protein, binds directly to gly-
cogen, the mechanism by which it interacts with SR mem-
branes is still unknown. It has been suggested that it could
be due to a membrane-associated domain or a domain for
interaction with a protein that binds to SR membranes
[10,12,13].
The objective of the present study was to investigate
whether PLB, one of the substrates of PP1, can also represent
a molecular target for GM. To this end we have produced the
human GM and PLB recombinant proteins and used co-
immunoprecipitation and biosensor methodologies to evi-
dence the physical interaction between GM and PLB. A meth-
od for predicting transmembrane domains was performed on
FEBS 21118 20-11-98 Cyaan Magenta Geel Zwart
0014-5793/98/$19.00 ß 1998 Federation of European Biochemical Societies. All rights reserved.
PII: S 0 0 1 4 - 5 7 9 3 ( 9 8 ) 0 1 3 6 4 - 7
*Corresponding author. Fax: (33) 2 99 28 04 44.
E-mail: isabelle_bertrand@sbphrd.com
Abbreviations: GM, G subunit = RG1 = PPP1R3 = protein phospha-
tase 1 (PP1) that targets the catalytic subunit (PP1C) to glycogen
particles and SR; SR, sarcoplasmic reticulum; SERCA, sarco(endo)-
plasmic reticulum calcium ATPase; ATPase, adenosine triphospha-
tase; DTT, dithiothreitol; MOPS, 3-(N-morpholino)propane sulfonic
acid; EGTA, ethylene glycol bis-(L-aminoethyl ether) N,N,NP,NP-
tetraacetic acid; SDS-PAGE, sodium dodecyl sulphate-polyacrylamide
gel electrophoresis; PBS-T, phosphate buffer saline-Tween 20; Ig,
immunoglobulin; Ig-HRP, Ig complexed to horseradish peroxidase;
ECL, enhanced chemiluminescence ; NHS, N-hydroxysuccimide ;
EDC, 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide; HBS, HEPES
buffer saline; RU, resonance unit; GL, targeting subunit for liver
glycogen; PTG, for protein targeting to glycogen; M110, myofibrils;
PCR, polymerase chain reaction
FEBS 21118FEBS Letters 439 (1998) 224^230
the 1122-residue sequence of GM and con¢rmed that the
protein is able to anchor to the SR membrane via its C-ter-
minal stretch. Together these data have led to a new way of
understanding the molecular events involved in SERCA 2a
activity.
2. Materials and methods
2.1. Antibodies and reagents
Anti-canine PLB monoclonal antibodies were obtained from Euro-
medex, France and Dr Philip Cohen (University of Dundee, UK)
provided sheep antibodies raised against GM subunit. Anti-mouse
Ig-HRP-linked whole antibody (from sheep) and anti-rabbit Ig-
HRP-linked whole antibody (from donkey) were purchased from
Amersham Life Science, France. Anti-sheep IgG-HRP-linked whole
molecule (from donkey) was purchased from Sigma. Protein A and G
Sepharose were purchased from Pharmacia Biotech, France.
2.2. Human PLB cDNA cloning
PLB encoding cDNA was generated according to the sequence
published by Fujii et al. [14], GenBank accession number m63603.
The sequence was modi¢ed by the addition of a HindIII site at the
5P end and an EcoRI site at the 3P end. Eight oligonucleotides were
synthesised on an Applied Biosystems 380B DNA synthesiser using
standard cyanoethyl phosphoramidite chemistry. The oligonucleotides
were gel-puri¢ed and assembled by pairs (OL1+OL2, OL3+OL4,
OL5+OL6 and OL7+OL8) into the full-length species (159 bp):
The sequence of PLB was then cloned into HindIII/EcoRI-digested
pCDNA3 vector (Invitrogen, Carlsbad, CA) to give pCDNA3-PLB
plasmid. PLB cDNA (173-bp fragment) was ampli¢ed by PCR from
pCDNA3-PLB plasmid using a speci¢c set of primers and subcloned
into pCITE 2b vector (Novagen, Madison, WI) digested by NcoI-
EcoRI in order to gain some e⁄ciency in producing PLB protein in
the rabbit reticulocyte translation/traduction system. A NcoI restric-
tion site was added to the sense primer at the 5P end overlapping with
the ATG initiation codon and allowing the PLB cloning in frame with
IRES (internal ribosomal entry site) in pCITE plasmid. The EcoRI
restriction site at the 5P end of the antisense primer was conserved.
The primers used were as follows: PLB-NcoI, 27 mer: 5P-TAGGATC-
CATGGAGAAAGTCCAATACC-3P ; PL-EcoRI, 20 mer: 5P-CGAA-
TTCTCAGAGAAGCATC-3P.
2.3. GM plasmid construct
cDNA encoding GM [15], GenBank accession number X78578, was
provided by Dr Philip Cohen. The corresponding sequence (3366 bp)
was inserted into pBluescript KS using the ClaI site at the 5P end and
the BamHI site at the 3P end.
2.4. Production of human PLB and GM in a rabbit reticulocyte lysate
system
Protein synthesis was achieved using an in vitro transcription/trans-
lation system according to the manufacturer’s recommended condi-
tions (TNT T7/T3-coupled reticulocyte lysate system, from Promega,
Madison, WI). Reactions were done including 60 WCi [35S]methionine.
Sense mRNA translation was performed using T7 RNA polymerase
coupled with T7 promoter (PLB protein synthesis) and T3 RNA
polymerase coupled with T3 promoter (GM protein synthesis). Neg-
ative control experiments were run by doing antisense translation
using alternative T3/T7 promoters with corresponding RNA polymer-
ase enzymes and a positive control experiment was done using luci-
ferase T7 control DNA. In vitro transcription-translation was per-
formed in a reaction volume of 25 Wl with 1 Wg of each construct
according to conditions recommended by manufacturer. The reaction
was incubated at 30‡C for 120 min and a 5-Wl aliquot of the synthes-
ised proteins was analysed by SDS-PAGE.
2.5. Immunoprecipitation of PLB and GM
6 Wl of [35S]PLB lysate (107 cpm) was immunoprecipitated with 5 Wl
of anti-canine PLB antibodies in a total volume of 1 ml PBS bu¡er at
4‡C for 2 h under stirring conditions. Then 50 Wl of protein A Se-
pharose was added to the medium and incubated at 4‡C for 45 min
under stirring conditions. Five successive washing steps were done,
Laemmli bu¡er (v/v) was added to the pellet, the solution was then
boiled 5 min and ¢nally centrifuged. The supernatant was loaded on
the gel and run on a 15% polyacrylamide gel. The same protocol was
applied for [35S]GM lysate (107 cpm), with sheep antibodies raised
against GM subunit (anti-GM) and with protein G Sepharose instead
of protein A Sepharose.
2.6. Co-immunoprecipitation of PLB and GM
The putative interaction between PLB and GM was investigated in
the following conditions: 2 Wl of PLB T7 lysate and 50 Wl GM T3
lysate were incubated with 943 Wl PBS at 4‡C for 1 h, 5 Wl of PLB
monoclonal antibody was added to the medium and incubation was
done at 4‡C for 2 h. Then, 50 Wl of protein A Sepharose was added
and incubated at 4‡C for 45 min under gentle stirring. After three
washes with PBS, the Laemmli bu¡er (v/v) was added to the pellet,
boiled for 5 min, centrifuged and the supernatant was loaded on the
gel and electrophoresed.
2.7. Revelation method for £uorographies
Proteins were ¢xed on the gel after migration. To increase detection
sensitivity of £uorography, the gel was then incubated with Amplify
reagent from Amersham. After drying, the gel was kept at 370‡C
overnight in contact with a hyper¢lm before revelation.
2.8. Biomolecular interaction using surface plasmon resonance
2.8.1. Covalent immobilisation of anti-canine PLB monoclonal anti-
bodies on biosensor Cm-5 chip. The aminosilane surface of the sensor
chip was activated by injection of a 1/1 mixture of N-hydroxysucci-
mide (NHS) and ethylenecarbodiimide (EDC) in order to form reac-
tive esters. After activation, monoclonal anti-PLB antibodies (1^5 Wg
(50 Wg/ml) in 0.01 M HEPES pH 7.4, 0.15 M NaCl, 3 mM EDTA and
0.005% v/v surfactant P20 (HBS bu¡er)) were injected on the Cm-5
sensor chip and immobilised on the surface for 10 min, then washed
with HBS bu¡er. Injection of a solution of ethanolamine in HBS
bu¡er deactivates the excess of reactive esters. Anti-myoglobin was
immobilised as reference £ow cell in order to control non-speci¢c
binding.
2.8.2. Capture of PLB to immobilised anti-PLB. Once covalently
coupled to the Cm-5 sensor chip, anti-PLB antibodies were used to
capture PLB; 30 Wl of 1/5 diluted PLB T7 lysate was injected at a £ow
rate of 10 Wl/min. When PLB binds the refractive index of the medium
at the surface of the sensor is changed in direct proportion to the
bound mass. This change was detected according to the principle of
surface plasmon resonance and was expressed in resonance units
(RU). Regeneration was done using 2.5% zwittergent in H2O at a
£ow rate of 10 Wl/min. Both anti-myoglobin £ow cell and antisense
PLB lysate were used as negative controls.
2.8.3. Binding of GM protein to captured PLB. 25 Wl of pure GM
lysate was injected over the Cm-5/anti- PLB/PLB surface. Regenera-
tion was done as mentioned above. Both anti-myoglobin £ow cell and
antisense GM lysate were used as negative controls.
2.9. Sequence analysis of GM
GM was analysed using the neural network-based system PHD
(Pro¢le fed neural network systems from HeiDelberg) in order to
identify a putative transmembrane domain. The method generated
several parameters like prH which represents the probability for as-
signing helical transmembrane regions as well as an index of reliabil-
ity, Rel. Details of the methodology have been reported by Rost et al.
[16].
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OL1: 5P-AGCTTCCCGGGATGGAGAAAGTCCAATACCTCACT-
CGCTCAGC-3P
OL2: 5P-CTTCTTATAGCTGAGCGAGTGAGGTATTGGACTTT-
CTCCATCCCGGGA-3P
OL3: 5P-TATAAGAAGAGCCTCAACCATTGAAATGCCTCAAC-
AAGCACGTCA-3P
OL4: 5P-TGTAGCTTTTGACGTGCTTGTTGAGGCATTTCAAT-
GGTTGAGGCT-3P
OL5: 5P-AAAGCTACAGAATCTATTTATCAATTTCTGTCTCAT-
CTTAATAT-3P
OL6: 5P-GCAAGAGACATATTAAGATGAGACAGAAATTGAT-
AAATAGATTC-3P
OL7: 5P-GTCTCTTGCTGATCTGTATCATCGTGATGCTTCTCT-
GAG-3P
OL8: 5P-AATTCTCAGAGAAGCATCACGATGATACAGATCA-3P
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3. Results
3.1. GM interacts speci¢cally with PLB
We have performed experiments to investigate if a biophys-
ical interaction occurs between the human proteins PLB and
GM using two di¡erent approaches.
First, immunoprecipitation followed by co-immunoprecipi-
tation experiments were carried out with the human proteins
[35S]GM and [35S]PLB produced in vitro from their respective
cDNAs. Immunoprecipitation of human PLB protein in the
presence of speci¢c monoclonal antibody shows that PLB was
produced in its monomeric form and to a lesser extent in its
pentameric form (Fig. 1A) whose full dissociation occurs in
SDS by application of heat [17]. In the presence of the poly-
clonal antibody raised against GM, human GM was detected
mainly as the expected 160-kDa protein (Fig. 1B), but to a
lower extent as a truncated 103-kDa protein. Antisense
mRNA translation products for PLB and GM used as control
experiments did not yield any immunoprecipitate suggesting
that native reticulocyte lysates are free of endogenous PLB
and GM proteins. Finally, the experiment illustrated in Fig.
1C and performed with monoclonal antibodies raised against
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Fig. 1. Co-immunoprecipitation experiments. A: Immunoprecipita-
tion of PLB. PLB synthesis was performed using an in vitro tran-
scription/translation system (rabbit reticulocyte lysate). 6 Wl of
[35S]PLB lysate was subjected to immunoprecipitation using 5 Wl of
anti-PLB antibodies at 4‡C for 2 h. Then 50 Wl of protein A Se-
pharose was added to the medium and incubation was done at 4‡C
for 45 min. After washing steps, Laemmli bu¡er (v/v) was added to
the pellet, the solution was boiled 5 min and ¢nally centrifuged.
The supernatant was loaded on the gel, run on polyacrylamide gel
electrophoresis and autoradiographed. Sense mRNA translation was
obtained using T7 RNA polymerase coupled with T7 promoter.
Negative controls (antisense) were run with T3 RNA polymerase.
PLB is mainly detected as a monomer of 6 kDa as indicated with
an arrow. Additional spots represent traces of oligomeric forms
(from dimer to pentamer). B: Immunoprecipitation of GM. GM
synthesis was performed in rabbit reticulocytes lysate as described
for PLB. 6 Wl of [35S]GM lysate was subjected to immunoprecipita-
tion using 5 Wl of anti-GM antibodies at 4‡C for 2 h as described
for PLB immunoprecipitation (A). Sense mRNA translation was ob-
tained using T3 RNA polymerase coupled with T3 promoter. Nega-
tive controls (antisense) were performed using T7 RNA polymerase.
The 1122-residue protein is detected at a molecular weight of
160 kDa although a truncated form, already reported in the litera-
ture, can also be observed at 103 kDa. C: Co-immunoprecipitation
of PLB (6 kDa) and GM (160 kDa) from lysates. PLB T7 lysate
was incubated with GM T3 lysate with relative concentrations of
2 Wl PLB and 50 Wl GM at 4‡C for 1 h. The resulting complex was
incubated with 5 Wl of anti-PLB antibodies and then precipitated by
50 Wl of protein A Sepharose at 4‡C for 45 min, washed, boiled and
subjected to SDS-PAGE (15% gel polyacrylamide). Autoradiography
analysis was performed by molecular analyst software from Bio-
Rad. All antibodies failed to reveal immunoreactive bands in lysates
prepared with antisense mRNA translation products for GM and
PLB.
6
C
Fig. 2. Biomolecular interaction of PLB and GM detected by sur-
face plasmon resonance. A: Immobilisation of anti-PLB antibodies.
Anti-PLB was immobilised on a dextran surface using EDC/NHS
chemistry as described in Section 2. Anti-PLB immobilisation indu-
ces a marked increase in response which is reduced during washout.
The observed relevant signal is measured after deactivation by etha-
nolamine and compared to the initial baseline. B: Interaction of
PLB to captured speci¢c antibodies. Once covalently coupled to the
Cm-5 sensor chip, anti-PLB antibodies were used to capture PLB;
30 Wl of 1/5 diluted PLB T7 lysate were injected at a £ow rate of 10
Wl/min. Regeneration was performed using 2.5% zwittergent in H2O
at a £ow rate of 10 Wl/min. C: Binding of GM to PLB. 25 Wl of
pure GM lysate was injected over the Cm-5/anti-PLB/PLB surface.
Regeneration was done using 2.5% zwittergent in H2O at a £ow
rate of 10 Wl/min. D: Binding on non-speci¢c £ow cell. Anti-myo-
globin has been immobilised as a control of non-speci¢c binding or
with GM antisense lysate injected as negative control of the interac-
tion with PLB.
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PLB clearly evidenced the presence of both proteins: 160 kDa
for GM and 6 kDa for the monomeric form of PLB. This
result demonstrates that the two proteins PLB and GM inter-
act physically. Furthermore, the 103-kDa peptide is also able
to interact with monomeric PLB but seems to be less stable
compared to GM and is di⁄cult to detect in immunoprecipi-
tation conditions (Fig. 1B). In co-immunoprecipitation, the
pentameric form of PLB was not seen (Fig. 1C).
In a second approach, we investigated the interaction be-
tween PLB and GM in real time using the biosensor technol-
ogy. Monoclonal antibodies raised against PLB were cova-
lently immobilised on the surface of a sensor chip (baseline)
to capture PLB (Fig. 2A). Recombinant human PLB lysate
was injected at a continuous £ow rate (10 Wl/min); interaction
with the speci¢c antibody led to a 104.2-RU signal after wash-
out and removal of unbound material (Fig. 2B). In contrast,
as control of non-speci¢c binding, a 24.7-RU response was
observed on the non-speci¢c £ow cell, in which anti-myoglo-
bin antibody was immobilised (Fig. 2D). Consequently, the
speci¢c PLB/anti-PLB response represents the di¡erence be-
tween anti-PLB £ow cell and anti-myoglobin £ow cell signals
(79.5 RU). At this step, the injection of GM (Fig. 2C) induced
a second association process between GM and PLB lysates
demonstrating that GM interacted physically with PLB. The
optimised volumes of the lysates containing the in vitro trans-
lated proteins used to visualise the interaction between GM
and PLB were 25 to 1, respectively. A 156.9-RU signal was
observed after washout of unbound GM on anti-PLB £ow cell
(Fig. 2D). The calculated speci¢c signal for GM/PLB interac-
tion is the di¡erence between anti-PLB £ow cell and anti-
myoglobin £ow cell signals, e.g. 105.9 RU. Therefore, the
speci¢c interaction between GM and PLB is represented by
the di¡erence 105.9379.5 = 26.4 RU where 79.5 is the speci¢c
signal between PLB and immobilised anti-PLB and 105.9 is
the speci¢c signal obtained between PLB+GM and immobi-
lised anti-PLB. In contrast, antisense mRNA translation
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Fig. 3. Structure prediction of GM. The whole sequence has been subjected to the PHD method [16]. A putative transmembrane domain has
been identi¢ed only in the 100-residue C-terminal stretch of the protein (underlined segment) as indicated by the statistical values. The ‘proba-
bilities’ are scaled to the interval 0^9, e.g. prH = 5 means that the ¢rst output node is 0.5^0.6. Secondary structure: HL: H = helical transmem-
brane region, blank = other (loop); PHD: Pro¢le network prediction HeiDelberg; Rel: reliability index of prediction (0^9); prH: ‘probability’
for assigning helical transmembrane region; prL: ‘probability’ for assigning loop; PHDF: ¢ltered prediction, i.e. too long transmembrane seg-
ments are split, too short ones are deleted.
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products used as negative controls for GM and PLB are de-
void of binding capacity (1153113 = 2 RU; Fig. 2D).
3.2. GM as an integral membrane protein
The neural network-based analysis performed on the 1122
residues of GM gave rise to the identi¢cation of a putative
unique transmembrane domain located at the very end of the
C-terminal stretch of the protein as indicated by prH values
ranging from 5 to 9. This domain is comprised of about
25 hydrophobic residues. Reliability of the prediction method
is monitored by the Rel index showing that the identi¢ed
segment PYFLLFLIFLITVYHYDLMIGLTFYVL is likely
to span the lipid bilayer (Fig. 3).
4. Discussion
Several mammalian regulatory proteins have been isolated
and characterised. Amongst them, GL targets PP1C to liver
glycogen [18,19], M110 is responsible for the association of
PP1 with the myo¢brils of skeletal muscle [20,21] and spino-
philin is a novel PP1 binding protein identi¢ed recently in
dendritic spines [22]. In fact, at least 15 regulatory subunits
able to interact with the same catalytic subunit PP1C have
been identi¢ed to date in mammals [11], allowing PP1 to
regulate diverse functions. It is conceivable that the interac-
tion of regulatory subunits with PP1C may be transitory and
mutually exclusive, leading to the formation of di¡erent com-
plexes in a dynamic way. Recently, the novel PP1 glycogen-
associated regulatory subunit identi¢ed in 3T3-L1 adipocytes
and termed PTG (for protein targeting to glycogen) has been
shown to exhibit a dual activity similarly to GM [23]. In
addition to targeting PP1 to the glycogen particle, PTG can
also form complexes with PP1 substrate enzymes that regulate
glycogen metabolism, namely glycogen synthase, glycogen
phosphorylase, and phosphorylase kinase. In this case, PTG
not only binds PP1C and glycogen but also co-localises PP1
with its substrate at the glycogen particles suggesting that
PTG is responsible for assembling metabolic enzymes for
the localised reception of intracellular signals [23,24]. In a
similar way, the present experiments suggest that GM, which
targets PP1C to both glycogen particles and the SR of striated
muscle [13], may localise PP1C close to its PLB substrate in
order to control speci¢cally the activation of the calcium
ATPase. Indeed, PLB is commonly viewed as a regulatory
protein which, when dephosphorylated, reduces or even sup-
presses the activity of SERCA 2a by decreasing its a⁄nity for
calcium. Phosphorylation either on serine 16 or threonine 17
or on both of them relieves the inhibitory e¡ect of PLB to-
wards SERCA 2a allowing the ATPase to pump calcium more
rapidly from the cytosol to the SR as illustrated in Fig. 4A [4].
By analogy with skeletal muscle, it has been suggested that
the complex of PP1C and GM associated with SR membranes
[25,26] likely represents the major PLB phosphatase in the
heart [6]. MacDougall et al. [6] showed that in a rabbit cardiac
muscle fraction enriched in SR membranes, PP1 accounted
for 90% of the associated PLB (serine 16 or threonine 17)
phosphatase activity. In heart tissue, the protein previously
identi¢ed in skeletal muscle has been reported to be a hetero-
dimer composed of a 37-kDa catalytic PP1C complexed to a
much larger subunit (GM) of about 160 kDa [6]. Another
study has shown that the glycogen-bound form of GM has
been previously puri¢ed as a heterodimer composed of the
37-kDa catalytic subunit described above and of a proteolyt-
ically sensitive 103-kDa glycogen binding subunit [27]. More-
over, Hubbard et al. [28] demonstrated that the intact GM
subunit is a 161-kDa protein and that the 103-kDa species
they called GP was a product of proteolysis. Interestingly,
we observed the presence of a 103-kDa peptide in our exper-
imental conditions, which is also able to interact with PLB as
shown in the co-immunoprecipitation experiments. Although
we cannot exclude that it is a proteolytic product of the re-
action, the 103-kDa peptide is more likely to result from an
internal translation initiation process commonly observed in
vitro.
Furthermore, the present experiments indicate that PP1 reg-
ulatory subunit GM, which is responsible for targeting the
catalytic subunit to its substrate ensuring subsequent dephos-
phorylation, is tightly and speci¢cally associated with PLB.
Human PLB is comprised of two main domains: an N-termi-
nal segment of about 30 residues extending in the cytosol and
a C-terminal domain of 22 hydrophobic residues which spans
membrane bilayers [29,30]. These two domains are involved in
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Fig. 4. Proposed three-step pathway for regulation of SERCA 2a via PP1/PLB interaction. A: SERCA 2a is displayed in an active form as
PLB is in its phosphorylated state. B: Heterotrimeric complex PP1C/GM/PLB involved in the dephosphorylation process of PLB: GM directs
PP1C towards the membrane protein PLB via its transmembrane domain. C: Dephosphorylated PLB interacts with SERCA 2a making it less
active and thus reducing the calcium uptake.
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cytosolic and intramembrane interactions with the calcium
pump and it has been reported that the inhibitory interaction
site lies entirely in the transmembrane sequences of PLB and
SERCA 2a [31]. When compared to PLB, GM is a large
protein of 1122 amino acids and it is established that its N-
terminal stretch is responsible for the binding of the catalytic
subunit PP1C [32,33]. A previous hydropathy analysis of the
amino acid sequence of GM had revealed a hydrophobic re-
gion likely to anchor the protein to the membrane of the SR
[12]. Therefore to further understand what structural features
could be involved in the interaction between GM and PLB, an
additional sequence analysis was performed on GM. It
showed that the hydrophobic residue-rich domain located be-
tween amino acids 1077 and 1103 possesses criteria of a pu-
tative transmembrane region able to anchor PP1 to the SR
lipid bilayer (Fig. 3), establishing a connection between PP1C
and PLB (Fig. 4B). Thus, a biophysical interaction should
exist in cardiac human cells between the regulatory subunit
GM and PLB as evidenced by this study with human re-
combinant proteins both by co-immunoprecipitation and by
the biosensor technology and we believe that such an inter-
action may occur at least through the transmembrane domain
of the two proteins as reported for the binding of PLB and
SERCA 2a [31]. All together, these results clearly demonstrate
that PLB is a molecular target for GM and this is consistent
with the role of the regulatory protein providing speci¢city to
a ubiquitously distributed catalytic PP1C.
Finally, the present work suggests that the disruption of the
interaction between GM and PLB would be highly speci¢c; in
this way PLB will remain in a phosphorylated state avoiding
its inhibitory e¡ect towards SERCA 2a. Therefore, the study
of GM/PLB interaction could represent a completely novel
pharmacological approach to increase calcium uptake by the
SR and thus to improve cardiac relaxation.
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